Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Geurts SME"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-9 z 9
    Tytuł:
    Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry.
    Autorzy:
    de Jong EJM; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Center, GROW, Maastricht University, Maastricht, the Netherlands.
    Mommers I; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Center, GROW, Maastricht University, Maastricht, the Netherlands.
    Fariña Sarasqueta A; Department of Pathology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands.
    van der Geest LG; Department of Research and Innovation, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.
    Heij L; Department of Surgery, School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, the Netherlands.; Department of General, Gastrointestinal, Hepatobiliary and Transplant Surgery, RWTH Aachen University Hospital, Aachen, Germany.; Institute of Pathology, RWTH Aachen University, Aachen, Germany.
    de Hingh IHJT; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.; GROW, Maastricht University, Maastricht, the Netherlands.
    Homs MYV; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands.
    Tjan-Heijnen VCG; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Center, GROW, Maastricht University, Maastricht, the Netherlands.
    Valkenburg-van Iersel LBJ; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Center, GROW, Maastricht University, Maastricht, the Netherlands.
    Wilmink JW; Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands.
    Geurts SME; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Center, GROW, Maastricht University, Maastricht, the Netherlands.
    de Vos-Geelen J; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Center, GROW, Maastricht University, Maastricht, the Netherlands.
    Pokaż więcej
    Corporate Authors:
    Dutch Pancreatic Cancer Group
    Źródło:
    Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2022 May; Vol. 61 (5), pp. 591-596. Date of Electronic Publication: 2022 Apr 05.
    Typ publikacji:
    Letter
    MeSH Terms:
    Adenocarcinoma*/drug therapy
    Duodenal Neoplasms*/drug therapy
    Pancreatic Neoplasms*/drug therapy
    Chemotherapy, Adjuvant ; Humans ; Palliative Care ; Registries
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Quantifying the duration of the preclinical detectable phase in cancer screening: a systematic review.
    Autorzy:
    Geurts SME; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
    Aarts AMWM; Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
    Verbeek ALM; Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
    Chen THH; Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan.
    Broeders MJM; Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.; Dutch Expert Centre for Screening, Nijmegen, The Netherlands.
    Duffy SW; Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
    Pokaż więcej
    Źródło:
    Epidemiology and health [Epidemiol Health] 2022; Vol. 44, pp. e2022008. Date of Electronic Publication: 2022 Jan 03.
    Typ publikacji:
    Systematic Review
    MeSH Terms:
    Breast Neoplasms*/diagnosis
    Breast Neoplasms*/epidemiology
    Colorectal Neoplasms*/diagnosis
    Colorectal Neoplasms*/epidemiology
    Bayes Theorem ; Early Detection of Cancer ; Female ; Humans ; Male ; Mammography ; Mass Screening ; Sensitivity and Specificity
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Healthcare Use during the Last Six Months of Life in Patients with Advanced Breast Cancer.
    Autorzy:
    Schmitz RSJM; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.
    Geurts SME; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.
    Ibragimova KIE; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.
    Tilli DJP; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.
    Tjan-Heijnen VCG; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.
    de Boer M; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2021 Oct 20; Vol. 13 (21). Date of Electronic Publication: 2021 Oct 20.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry.
    Autorzy:
    Claessens AKM; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; Department of Medical Oncology, Zuyderland Medical Center, PO BOX 5500, 6130 MB, Sittard-Geleen, The Netherlands.
    Ramaekers BLT; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.
    Lobbezoo DJA; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.
    van Kampen RJW; Department of Medical Oncology, Zuyderland Medical Center, PO BOX 5500, 6130 MB, Sittard-Geleen, The Netherlands.
    de Boer M; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.
    van de Wouw AJ; Department of Internal Medicine, VieCuri Medical Center, PO BOX 1926, 5900 BX, Venlo, The Netherlands.
    Dercksen MW; Department of Internal Medicine, Máxima Medical Center, PO BOX 90052, 5600 PD, Eindhoven, The Netherlands.
    Geurts SME; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.
    Joore MA; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.
    Tjan-Heijnen VCG; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands. .
    Pokaż więcej
    Źródło:
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2020 Dec; Vol. 29 (12), pp. 3363-3374. Date of Electronic Publication: 2020 Aug 20.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Breast Neoplasms/*psychology
    Quality of Life/*psychology
    Aged ; Cohort Studies ; Cross-Sectional Studies ; Female ; Humans ; Male ; Registries ; Surveys and Questionnaires
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.
    Autorzy:
    Pouwels XGLV; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre +, Maastricht, The Netherlands.; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.
    Ramaekers BLT; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre +, Maastricht, The Netherlands.
    Geurts SME; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre +, Maastricht, The Netherlands.
    Erdkamp F; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands.
    Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands.
    Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
    van de Wouw AJ; Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands.
    Dercksen MW; Department of Internal Medicine, Máxima Medical Centre, Eindhoven, The Netherlands.
    Smilde TJ; Department of Internal Medicine, Jeroen Bosch Hospital, Hertogenbosch, The Netherlands.
    Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis, Weert, The Netherlands.
    van Riel JMGH; Department of Internal Medicine, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
    Pepels MJ; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands.
    Heijnen-Mommers J; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre +, Maastricht, The Netherlands.
    Tjan-Heijnen VCG; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre +, Maastricht, The Netherlands.
    de Boer M; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre +, Maastricht, The Netherlands.
    Joore MA; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre +, Maastricht, The Netherlands.; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
    Pokaż więcej
    Źródło:
    Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2020 Sep; Vol. 59 (9), pp. 1123-1130. Date of Electronic Publication: 2020 Jun 16.
    Typ publikacji:
    Comparative Study; Journal Article
    MeSH Terms:
    Models, Economic*
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Breast Neoplasms/*drug therapy
    Drug Costs/*statistics & numerical data
    Furans/*therapeutic use
    Ketones/*therapeutic use
    Antineoplastic Combined Chemotherapy Protocols/economics ; Breast Neoplasms/diagnosis ; Breast Neoplasms/economics ; Breast Neoplasms/mortality ; Computer Simulation ; Cost-Benefit Analysis ; Disease Progression ; Female ; Furans/economics ; Humans ; Insurance, Health, Reimbursement/economics ; Insurance, Health, Reimbursement/statistics & numerical data ; Ketones/economics ; Middle Aged ; Netherlands/epidemiology ; Progression-Free Survival ; Quality-Adjusted Life Years ; Registries/statistics & numerical data
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer.
    Autorzy:
    de Vos-Geelen J; Department of Internal Medicine, Division of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
    Hoebers FJP; Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
    Geurts SME; Department of Internal Medicine, Division of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
    Hoeben A; Department of Internal Medicine, Division of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
    de Greef BTA; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Center, Maastricht, The Netherlands.
    Voncken FEM; Department of Radiation Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
    Bogers JHA; Radiotherapiegroep Arnhem, Arnhem, The Netherlands.
    Braam PM; Department of Radiotherapy, Nijmegen, The Netherlands.
    Muijs CKT; Department of Radiotherapy, University Medical Center Groningen, Groningen, The Netherlands.
    de Jong MA; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
    Kasperts N; Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands.
    Rozema T; Insituut Verbeeten, Tilburg, The Netherlands.
    Jeene PM; Department of Radiotherapy, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.; Radiotherapiegroep, Deventer, The Netherlands.
    Blom GJ; Department of Radiation Oncology, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.
    van Dieren JM; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
    Hulshof MCCM; Department of Radiotherapy, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
    van Laarhoven HWM; Department of Medical Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
    Grabsch HI; Department of Pathology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.; Pathology & Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
    Lemmens VEPP; Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), The Netherlands.; Department of Public Health, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
    Tjan-Heijnen VCG; Department of Internal Medicine, Division of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
    Nieuwenhuijzen GAP; Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
    Pokaż więcej
    Źródło:
    Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2020 Aug; Vol. 59 (8), pp. 895-903. Date of Electronic Publication: 2020 Apr 22.
    Typ publikacji:
    Journal Article; Multicenter Study; Observational Study
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Carcinoma, Squamous Cell/*therapy
    Chemoradiotherapy/*methods
    Esophageal Neoplasms/*therapy
    Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/administration & dosage ; Carcinoma, Squamous Cell/mortality ; Carcinoma, Squamous Cell/pathology ; Chemoradiotherapy/adverse effects ; Cisplatin/administration & dosage ; Esophageal Neoplasms/mortality ; Esophageal Neoplasms/pathology ; Female ; Humans ; Logistic Models ; Male ; Middle Aged ; Netherlands ; Paclitaxel/administration & dosage ; Propensity Score ; Proportional Hazards Models ; Radiotherapy Dosage ; Retrospective Studies ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands.
    Autorzy:
    Schneider PP; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre+, Maastricht, The Netherlands.; School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom.
    Pouwels XGLV; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre+, Maastricht, The Netherlands.
    Passos VL; Department of Methodology and Statistics, CAPHRI Care and Public Health Research Institute Maastricht University, Maastricht, The Netherlands.
    Ramaekers BLT; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre+, Maastricht, The Netherlands.
    Geurts SME; Department of Medical Oncology, GROW - School of Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
    Ibragimova KIE; Department of Medical Oncology, GROW - School of Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
    de Boer M; Department of Medical Oncology, GROW - School of Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
    Erdkamp F; Zuyderland medical center, Sittard-Geleen, The Netherlands.
    Vriens BEPJ; Catharina hospital, Eindhoven, The Netherlands.
    van de Wouw AJ; VieCuri Medical Center, Venlo, The Netherlands.
    den Boer MO; Laurentius hospital Roermond, The Netherlands.
    Pepels MJ; Elkerliek Hospital, Helmond, The Netherlands.
    Tjan-Heijnen VCG; Department of Medical Oncology, GROW - School of Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
    Joore MA; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre+, Maastricht, The Netherlands.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2020 Apr 09; Vol. 15 (4), pp. e0230909. Date of Electronic Publication: 2020 Apr 09 (Print Publication: 2020).
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Breast Neoplasms/*economics
    Terminal Care/*economics
    Aged ; Breast Neoplasms/mortality ; Breast Neoplasms/therapy ; Female ; Hospital Costs ; Hospitalization/economics ; Humans ; Linear Models ; Logistic Models ; Middle Aged ; Netherlands ; Palliative Care/economics ; Survival Rate
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry.
    Autorzy:
    Pouwels XGLV; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands.; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.
    Geurts SME; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.
    Ramaekers BLT; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands.
    Erdkamp F; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands.
    Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands.
    Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
    van de Wouw AJ; Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands.
    Dercksen MW; Department of Internal Medicine, Máxima Medical Centre, Veldhoven/Eindhoven, The Netherlands.
    Smilde TJ; Department of Internal Medicine, Jeroen Bosch Hospital, Hertogenbosch, The Netherlands.
    Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis, Weert, The Netherlands.
    Riel JMV; Department of Internal Medicine, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
    Pepels MJ; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands.
    Heijnen-Mommers J; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.
    Joore MA; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands.; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
    Tjan-Heijnen VCG; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.
    de Boer M; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.
    Pokaż więcej
    Źródło:
    Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2020 Jan; Vol. 59 (1), pp. 82-89. Date of Electronic Publication: 2019 Oct 04.
    Typ publikacji:
    Journal Article; Multicenter Study
    MeSH Terms:
    Breast Neoplasms/*drug therapy
    Furans/*therapeutic use
    Ketones/*therapeutic use
    Adult ; Aged ; Breast Neoplasms/epidemiology ; Breast Neoplasms/pathology ; Female ; Humans ; Middle Aged ; Multivariate Analysis ; Netherlands/epidemiology ; Registries ; Survival Rate ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Time patterns of recurrence and second primary tumors in a large cohort of patients treated for oral cavity cancer.
    Autorzy:
    Brands MT; Department of Oral and Maxillofacial Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.
    Smeekens EAJ; Department of Oral and Maxillofacial Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.
    Takes RP; Department of Ear Nose and Throat Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.
    Kaanders JHAM; Department of Radiation Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
    Verbeek ALM; Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
    Merkx MAW; Department of Oral and Maxillofacial Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.
    Geurts SME; Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
    Pokaż więcej
    Źródło:
    Cancer medicine [Cancer Med] 2019 Sep; Vol. 8 (12), pp. 5810-5819. Date of Electronic Publication: 2019 Aug 10.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Time-to-Treatment*
    Mouth Neoplasms/*surgery
    Neoplasm Recurrence, Local/*diagnosis
    Neoplasms, Second Primary/*diagnosis
    Squamous Cell Carcinoma of Head and Neck/*surgery
    Adult ; Female ; Humans ; Incidence ; Intention to Treat Analysis ; Longitudinal Studies ; Male ; Middle Aged ; Mouth Neoplasms/epidemiology ; Mouth Neoplasms/pathology ; Neoplasm Recurrence, Local/epidemiology ; Neoplasms, Second Primary/epidemiology ; Netherlands/epidemiology ; Retrospective Studies ; Squamous Cell Carcinoma of Head and Neck/epidemiology ; Squamous Cell Carcinoma of Head and Neck/pathology ; Surgical Procedures, Operative/methods ; Survival Rate ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-9 z 9

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies